Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 7, 2025
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
GlobeNewswire
·
May 7, 2025
CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
Jack.org Appoints New President and Chief Executive Officer
GlobeNewswire
·
May 7, 2025
Photo Caption: Michael Braithwaite joins Jack.org as President and CEO on June 16 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Jack.org is thrilled to announce the appointment of Michael Braithwaite (he/him) as its new President and Chief Executive Officer ( …
Jack.org nomme un nouveau président et directeur général
GlobeNewswire
·
May 7, 2025
Légende de la photo : Michael Braithwaite deviendra le nouveau PDG de Jack.org le 16 juin. TORONTO, 07 mai 2025 (GLOBE NEWSWIRE) -- Jack.org est ravi d’annoncer la nomination de Michael Braithwaite (il/lui) au poste de nouveau président et directeur …
Respect Together Honors 50 Years of Impact and Charts a New Era for Survivors
GlobeNewswire
·
May 7, 2025
Hershey, Pennsylvania, May 07, 2025 (GLOBE NEWSWIRE) -- Respect Together commemorated its 50th Anniversary on Wednesday evening with a powerful event at the Hershey Country Club, bringing together survivors, advocates, community leaders, and public …
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
GlobeNewswire
·
May 7, 2025
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE …
NewGenIVF Introduces NewGenSort to Support Men’s Reproductive Health Across Asia
GlobeNewswire
·
May 7, 2025
BANGKOK, May 07, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced an …
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
GlobeNewswire
·
May 7, 2025
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. ( …
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
GlobeNewswire
·
May 7, 2025
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of …
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire
·
May 7, 2025
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for …
Arialief Complaints Explained: 2025 Customer Reviews Analyzed & Verified
GlobeNewswire
·
May 7, 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- In 2025, nerve pain remains one of the most widespread yet under-discussed health challenges. Clinically known as peripheral neuropathy, this condition affects millions worldwide and manifests in various forms, …
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
GlobeNewswire
·
May 7, 2025
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., …
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
GlobeNewswire
·
May 7, 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
GlobeNewswire
·
May 7, 2025
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in …
Thérapeutique Knight annonce la relance de ONICIT® au Brésil et au Mexique
GlobeNewswire
·
May 7, 2025
MONTRÉAL, 07 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd'hui la prise en charge complète des activités commerciales et la relance de …
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire
·
May 7, 2025
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at …
Repligen Corporation to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC …
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline …
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
GlobeNewswire
·
May 7, 2025
– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination …
The Joint Corp. to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 7, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced that President and CEO Sanjiv Razdan and CFO Jake Singleton are scheduled to participate in …